In Reply: TP53 Alteration Status and Tumor Mutational Burden Score: Prevalence and Prognosis in Head and Neck Squamous Cell Carcinoma

Kimberly M Burcher; Harper L Wilson; Elena Gavrila; Arianne Abreu; Ralph B D'Agostino; Wei Zhang; Mercedes Porosnicu

doi:10.1093/oncolo/oyac088

In Reply: TP53 Alteration Status and Tumor Mutational Burden Score: Prevalence and Prognosis in Head and Neck Squamous Cell Carcinoma

Oncologist. 2022 Jul 5;27(7):e606-e607. doi: 10.1093/oncolo/oyac088.

Authors

Kimberly M Burcher¹, Harper L Wilson², Elena Gavrila³, Arianne Abreu⁴, Ralph B D'Agostino⁵, Wei Zhang⁶, Mercedes Porosnicu⁷

Affiliations

¹ Department of Internal Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC, USA.
² Department of Anesthesiology & Perioperative Medicine, Medical University of South Carolina College of Medicine, Charleston, SC, USA.
³ Wake Forest School of Medicine, Winston-Salem, Salem, VA, USA.
⁴ Department of Internal Medicine, LewisGale Medical Center, Salem, VA, USA.
⁵ Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, NC, USA.
⁶ Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
⁷ Medical Oncology and Hematology, Wake Forest Baptist Medical Center, Winston-Salem, NC, USA.

Abstract

This Letter to the Editor responds to recent comments by Jiang et al. and joins the recommendation for further investigations into the role of TP53alteration status and TMB as predictors of response to immunotherapy and survival in head and neck squamous cell carcinoma.

Publication types

Letter
Research Support, N.I.H., Extramural
Comment

MeSH terms

Biomarkers, Tumor
Head and Neck Neoplasms* / epidemiology
Head and Neck Neoplasms* / genetics
Humans
Prevalence
Prognosis
Squamous Cell Carcinoma of Head and Neck / genetics
Tumor Suppressor Protein p53 / genetics

Substances

Biomarkers, Tumor
TP53 protein, human
Tumor Suppressor Protein p53

Abstract

Publication types

MeSH terms

Substances

Grants and funding